Video

Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Christine Ryan, MD, hematology/oncology fellow, the Department of Medical Oncology, the Dana-Farber Cancer Institute, discusses the significance of data for ibrutinib (Imbruvica) plus obinutuzumab (Gazyva) in relapsed/refractory chronic lymphocytic leukemia (CLL). 

A phase 1b trial (NCT02537613) investigated potential sequencing options for the combination of ibrutinib and obinutuzumab in patients with relapsed/refractory CLL who have received at least 1 prior line of CLL-directed therapy.

Data shared at the 2022 EHA Congress showed that progression-free survival (PFS) and overall survival rates were similar for all patients treated with the doublet, including those in high-risk subgroups, Ryan says. Among the overall population, the combination elicited a 4-year PFS rate of 74%, Ryan explains.

The findings from the phase 1b study have set the stage for addition evaluation of ibrutinib plus obinutuzumab in relapsed/refractory CLL, Ryan continues. This combination is particularly intriguing because it generated responses in all 3 patients in the phase 1b trial who previously progressed on venetoclax (Venclexta), Ryan concludes.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS